Sputnik V vaccine 92?fective against coronavirus, claims Russia
The first interim data analysis of the Sputnik V vaccine against Covid-19 Phase III clinical trials in the Russian Federation demonstrated 92 per cent efficacy.
Currently, Sputnik V Phase III clinical trials are approved and are undergoing in Belarus, UAE, Venezuela, and other countries, as well as Phase II-III in India.
Trials conducted under the civil use of the vaccine in Russia (not being a part of clinical trials) based on the monitoring of 10,000 vaccinated confirmed vaccine efficacy at a rate of over 90 per cent.
There were no unexpected adverse events during the trials. The monitoring of the participants is ongoing.
Efficacy was demonstrated on the basis of a first interim analysis obtained 21 days after the first injection.